Financials data is unavailable for this security.
View more
Year on year Dicot Pharma AB had net income fall 39.05% from a loss of 31.76m to a larger loss of 44.16m despite revenues that grew 89.43% from 120.41k to 228.09k over the same period.
| Gross margin | -21,705.50% |
|---|---|
| Net profit margin | -24,829.54% |
| Operating margin | -25,388.90% |
| Return on assets | -55.17% |
|---|---|
| Return on equity | -59.55% |
| Return on investment | -59.55% |
More ▼
Cash flow in SEKView more
In 2023, Dicot Pharma AB increased its cash reserves by 404.88%, or 37.96m. Cash Flow from Financing totalled 83.19m or 36,473.13% of revenues. In addition the company used 45.23m for operations while cash from investing was breakeven.
| Cash flow per share | -0.0503 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0744 |
|---|---|
| Tangible book value per share | 0.0744 |
More ▼
Balance sheet in SEKView more
| Current ratio | 16.76 |
|---|---|
| Quick ratio | 15.92 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
